Clinical trials: Ivermectin
Covid19, COVID-19 Pneumonia
Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19
Ivermectin is currently being utilized by a number of physicians in the local area. My objective will be to enroll these patients at the time of their evaluation for COVID-19 infection and to follow their progress through their…
- Conditions
- Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Bronchitis
- Trial name
- NCT05045937
- Testing
- Ivermectin
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Patrick Robinson
Onchocerciasis
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in…
- Trial name
- NCT04311671
- Testing
- Moxidectin, Ivermectin, Albendazole
- Where
- 2 sites in Côte d’Ivoire, Democratic Republic of the Congo
- Volunteers
- 12,979 people, healthy volunteers welcome
- Sponsor
- Medicines Development for Global Health
Mansonelliasis, Pruritus
Epidemiology and Control of Mansonella Perstans Infection in Uganda
Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available.
- Conditions
- Mansonelliasis, Pruritus, Lymphoedema, Abdominal Pains
- Trial name
- NCT00215280
- Testing
- ivermectin and albendazole
- Where
- Uganda
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- DBL -Institute for Health Research and Development
COVID
Prophylactic Ivermectin in COVID-19 Contacts
asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms \& diagnosis of COVID -19
- Trial name
- NCT04422561
- Testing
- Ivermectin Tablets
- Where
- Egypt
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Lymphatic Filariasis, Helminth Infection
Twice Yearly Treatment for the Control of LF
The Global Program for the Elimination of Lymphatic Filariasis (GPELF) has been in operation sing the year 2000, with the aim of eliminating the disease by the year 2020, following 5-6 rounds of effective annual Mass Drug…
- Trial name
- NCT03036059
- Testing
- 400 μg/kg Ivermectin + 400 mg Albendazole
- Where
- Ghana
- Volunteers
- 1,462 people, healthy volunteers welcome
- Sponsor
- Noguchi Memorial Institute for Medical Research